EQS-News: Eckert & Ziegler: Berenberg Starts Coverage with a “Buy” Recommendation and a Price Target of € 24 – Price Potential 47%

Berlin, 9 September 2025. Eckert & Ziegler SE (ISIN DE0005659700), a leading supplier of isotope technology components for nuclear medicine and measurement technology, will be rated by the Hamburg-based private bank Joh. Berenberg, Gossler & Co. KG from now on. In their initial study, the analysts issue a “Buy” recommendation with a price target of € 24.00. This corresponds to a price potential of 46.8% compared to the Xetra closing price of € 16.35 on 8 September 2025.

The analysts emphasize in particular the strong market position of Eckert & Ziegler SE, which is benefiting from rising demand for diagnostic and therapeutic radioisotopes in nuclear medicine.

The complete research report is available in the Investors section of the company's website:
https://www.ezag.com/investors/analyses/

About Eckert & Ziegler.
Eckert & Ziegler SE with more than 1.000 employees is a leading specialist for isotope-related components in nuclear medicine and radiation therapy. The company offers a broad range of services and products for the radiopharmaceutical industry, from early development work to contract manufacturing and distribution. Eckert & Ziegler shares (ISIN DE0005659700) are listed in the TecDax index of Deutsche Börse.
Contributing to saving lives.

Your contact:
Eckert & Ziegler SE, Karolin Riehle, Investor Relations
Robert-Rössle-Str. 10, 13125 Berlin, Germany
Tel.: +49 (0) 30 / 94 10 84-138, karolin.riehle@ezag.de, www.ezag.com